Michael Dengler

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, Ella R Thompson, Xiangting Chen, Tamia Nguyen, Mary Ann Anderson, David Alan Westerman, John F Seymour, Constantine S Tam, Michael A Dengler, David CS Huang, Andrew Wei, Andrew W Roberts

Journal article  |  2020  |  Blood

Venetoclax (Ven) is an effective element of treatments for chronic lymphocytic leukemia (CLL) with high response rates observed in..

Flexible Usage and Interconnectivity of Diverse Cell Death Pathways Protect against Intracellular Infection

Marcel Doerflinger, Yexuan Deng, Paul Whitney, Ranja Salvamoser, Sven Engel, Andrew J Kueh, Lin Tai, Annabell Bachem, Elise Gressier, Niall D Geoghegan, Stephen Wilcox, Kelly L Rogers, Alexandra L Garnham, Michael A Dengler, Stefanie M Bader, Gregor Ebert, Jaclyn S Pearson, Dominic De Nardo, Nancy Wang, Chenying Yang, et al.

Journal article  |  2020  |  Immunity

Programmed cell death contributes to host defense against pathogens. To investigate the relative importance of pyroptosis, necropt..

Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma

Michael A Dengler, Charis E Teh, Rachel Thijssen, Lahiru Gangoda, Ping Lan, Marco J Herold, Daniel H Gray, Gemma L Kelly, Andrew W Roberts, Jerry M Adams

Journal article  |  2020  |  Oncogene

Apoptosis-regulating BCL-2 family members, which can promote malignant transformation and resistance to therapy, have become prime..

Characterization of a novel human BFL-1-specific monoclonal antibody

Lahiru Gangoda, Charis E Teh, Michael A Dengler, Sarah A Best, Clare E Weeden, Lin Tai, Erinna F Lee, Walter D Fairlie, Kate D Sutherland, Leonard C Harrison, Daniel H Gray, Andreas Strasser, Marco J Herold

Journal article  |  2020  |  Cell Death & Differentiation

BAX Activation: Mutations Near Its Proposed Non-canonical BH3 Binding Site Reveal Allosteric Changes Controlling Mitochondrial Association

Michael A Dengler, Adeline Y Robin, Leonie Gibson, Mark X Li, Jarrod J Sandow, Sweta Iyer, Andrew Webb, Dana Westphal, Grant Dewson, Jerry M Adams

Journal article  |  2019  |  Cell Reports

Targeting Mcl-1 is a promising strategy to kill mantle cell lymphoma cells

Michael A Dengler, Charis E Teh, Marco J Herold, Andrew W Roberts, Jerry M Adams

Conference Proceedings  |  2019  |  CELL DEATH DISCOVERY

Subtle Changes in the Levels of BCL-2 Proteins Cause Severe Craniofacial Abnormalities

Stephanie Grabow, Andrew J Kueh, Francine Ke, Hannah K Vanyai, Bilal N Sheikh, Michael A Dengler, William Chiang, Samantha Eccles, Ian M Smyth, Lynelle K Jones, Frederic J de Sauvage, Mark Scott, Lachlan Whitehead, Anne K Voss, Andreas Strasser

Journal article  |  2018  |  Cell Reports

An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis

Annette M Staiger, Jasmin Duppel, Michael A Dengler, Heiko van der Kuip, Matthias C Voehringer, Walter E Aulitzky, Andreas Rosenwald, German Ott, Heike Horn

Journal article  |  2017  |  Leukemia & Lymphoma

BAK alpha 6 permits activation by BH3-only proteins and homooligomerization via the canonical hydrophobic groove

Mark Xiang Li, Iris KL Tan, Stephen B Ma, Colin Hockings, Tobias Kratina, Michael A Dengler, Amber E Alsop, Ruth M Kluck, Grant Dewson

Journal article  |  2017  |  Proceedings of the National Academy of Sciences of the United States of America

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.

MA Dengler, A Weilbacher, M Gutekunst, AM Staiger, MC Vöhringer, H Horn, G Ott, WE Aulitzky, H van der Kuip

Journal article  |  2014  |  Cell Death and Disease

Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm with transient response to conventional chemotherapy. We here invest..